Dr. John M. Dibianco, MD

Dr. Dibianco practices at UF Health Shands Hospital in Gainesville, Florida, part of UF Health.

Dr. Dibianco's NPI, 1821482845, was assigned on March 27, 2015. Dr. Dibianco graduated from Ross University School of Medicine in 2014. Dr. Dibianco's Michigan license number on file is 4301501944.

Dr. Dibianco's primary practice is UF Health Shands Hospital, at 1600 SW Archer Rd, Gainesville, FL 32610 in Alachua County. The practice phone is (352) 265-8000.

Dr. Dibianco's primary practice is UF Health Shands Hospital in Gainesville, Florida, part of UF Health. Dr. Dibianco is also affiliated with University Hospital. The medical group on file is UF Health Physicians.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dibianco practices, 2 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Dibianco's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Dibianco is board certified in urology by the American Board of Urology. Dmand AI has Dr. Dibianco's licenses on file in 4 states: Michigan, Florida, District of Columbia and Virginia.

Dmand AI lists bladder disease, enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney cysts, kidney removal surgery, kidney stone disease and kidney stones among the conditions Dr. Dibianco treats.

CMS data shows 3,048 Medicare services from Dr. Dibianco across 25 procedure codes in 2024, for 703 Medicare patients. Medicare paid $134,593 for them.

CMS counts 703 Medicare patients who saw Dr. Dibianco in 2024. The largest group is 65 to 74, with 321 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 11% are also on Medicaid. Their average risk score is 1.56, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dibianco's median patient age at 74, with 15% women.

In 2024, Dr. Dibianco wrote 380 Medicare Part D claims for 166 patients. 91% of them were for generic drugs. CMS names the drug for 280 of them, across 7 drugs with 11 or more claims each, at $26,331 in total drug cost. In 2023, CMS named 240 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Dibianco for performance year 2024, reported individually. Dr. Dibianco accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dibianco as offering telehealth. CMS counts 69 procedures of prostate resection by Dr. Dibianco, more than 98% of the clinicians it reports for that procedure.

Dmand AI links 39 papers to Dr. Dibianco, published from 2014 to 2025. 2023 was the busiest year, with 5. The most frequent topics are Kidney Calculi, Ureteroscopy and Ureteral Calculi. Dr. Dibianco has published most often in Urology. Dr. Dibianco's most frequent co-authors are Khurshid Ridwan Ghani, MD, Patrick Theodore Gomella, MD, MPH and Rabii Madi, MD.

Dmand AI links Dr. Dibianco to 1 clinical trial. Conditions studied include Ureterolithiasis and Ureteral Diseases.

CMS Open Payments shows 41 general payments to Dr. Dibianco from 13 drug and device companies from 2021 to 2025. Consulting fees make up the largest share, 38% of the total. Richard Wolf Medical Instruments Corp. paid the most, $5,736.

Dr. Dibianco graduated from Ross University School of Medicine in 2014.

Dr. Dibianco is in network with 17 carriers, including Aetna, Excellus BlueCross BlueShield and Health Alliance Plan. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.